Ultime notizie per Spruce Biosciences (NASDAQ:SPRB) Azioni

Spruce Biosciences

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Spruce Biosciences Inc

SPAREBANKEN 1 OSTLANDET by Sparebank 1 Ostlandet

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) with a Neutral.

News

Reiteration

Analyst Ratings

SPRB

HC Wainwright & Co. Reiterates Neutral on Spruce Biosciences

RBC Capital analyst Gregory Renza reiterates Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) with a Sector Perform and maintains $2 price target.

Price Target

RBC Capital Reiterates Sector Perform on Spruce Biosciences, Maintains $2 Price Target

Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 31.25 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.61 million which beat the analyst consensus estimate of $1.50 million by 7.69 percent. This is a 25.64 percent decrease over sales of $2.17 million the same period last year.

Earnings

Earnings Beats

Spruce Biosciences Q2 EPS $(0.22) Beats $(0.30) Estimate, Sales $1.61M Beat $1.50M Estimate

Oppenheimer analyst Hartaj Singh maintains Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) with a Outperform and lowers the price target from $4 to $3.

Oppenheimer Maintains Outperform on Spruce Biosciences, Lowers Price Target to $3

Biotech

Health Care

Contracts

General

Spruce Biosciences And HMNC Brain Health Collaborate To Develop Spruce's Investigational Product Candidate, Tildacerfont With HMNC's Companion Diagnostic For Major Depressive Disorder,  HMNC To Initiate Phase 2 Study In Q4 2024

Spruce Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) and HMNC Brain Health GmbH have collaborated to develop Spruce&#8217;s investigational product candidate, tildacerfont, and HMNC&#8217;s companion diagnostic, the proprietary Cortibon Genetic Selection Tool for major depressive disorder (MDD).&nbsp;
Spruce Biosciences is a late-stage biopharmaceutical company developing its wholly-owned product candidate, tildacerfont, for classic congenital adrenal hyperplasia, polycystic ovary syndrome, and MDD.
&#8220;We believe that Cortibon has the potential to enable tildacerfont to be advanced as a precision therapeutic for personalized medicine in patients with MDD,&#8221; said Javier Szwarcberg, CEO of Spruce Biosciences. &#8220;Hyperactive CRF neurotransmission and CRF1 receptor signal transduction are critical mechanisms for stress pathophysiology that may lead to major depression. Tildacerfont may mediate responses to stress, which has the potential to address up to 50% of MDD patients worldwide using Cortibon.&#8221;
&#8220;We are excited to collaborate with HMNC and initiate a Phase 2 proof-of-concept study of tildacerfont and Cortibon for the treatment of MDD later this year,&#8221;&nbsp;Szwarcberg added.
Under the agreement, HMNC will fund and conduct a Phase 2 proof-of-concept study of tildacerfont in MDD patients, who will be screened using Cortibon.
Spruce has the option to in-license exclusive worldwide rights to Cortibon after the completion of the study, if the results are positive.
If Spruce exercises its option, it will be responsible for the future worldwide development and commercialization of tildacerfont and Cortibon for MDD under a collaboration framework that leverages HMNC&#8217;s ongoing expertise in precision psychiatry and companion diagnostics.
Under the license terms, HMNC would be entitled to receive certain milestone payments and tiered royalties on net sales of tildacerfont in MDD.&nbsp;
Cortibon is HMNC&#8217;s proprietary companion diagnostic. By utilizing genetic markers, Cortibon aims to identify MDD patients who are more likely to respond to CRF1 receptor antagonism, thereby enhancing treatment outcomes and reducing the trial-and-error period typical in depression treatment.
Price Action: SPRB shares closed at $0.72 on Monday.

Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder

<ul>
<li>Significant Reduction in Dehydroepiandrosterone Sulfate (DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline</li>
<li>Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed</li>
<li>Tildacerfont was Well-Tolerated with No Safety Signals</li>
</ul>

Spruce Biosciences Presented Results From Phase 2 POWER Study Of Tildacerfont For Polycystic Ovary Syndrome At The 2024 Annual Meeting Of The Endocrine Society

Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 30 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $2.02 million which beat the analyst consensus estimate of $1.16 million by 74.14 percent. This is a 2.85 percent increase over sales of $1.96 million the same period last year.

Spruce Biosciences Q1 EPS $(0.28) Beats $(0.29) Estimate, Sales $2.02M Beat $1.16M Estimate

Spruce Biosciences Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares plummeted on Thursday after the company released topline results from its CAHmelia-203 Phase 2b study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37701200/why-is-rare-endocrine-disorder-focused-spruce-biosciences-stock-plummeting-on-thursday" rel="noreferrer noopener">pediatric classic CAH</a>.
The CAHmelia-203 study did not achieve the primary efficacy endpoint of the assessment of dose response for the change in A4 from baseline to week 12.
The preliminary pharmacokinetic analysis of the CAHptain-205 study suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.
HC Wainwright notes that despite considering tildacerfont an active drug, the setback in the CAHmelia-203 trial has created uncertainty about its future development and regulatory submission timeline.&nbsp;
Consequently, they are downgrading their rating on the shares from Buy to Neutral, with no specified price target. They await more clarity on tildacerfont&#8217;s long-term prospects and the results of the upcoming CAHmelia-204 trial, which is expected to release data later this year.
RBC Capital Markets&nbsp;said that while tildacerfont was well-tolerated, its efficacy and clinical profile were questionable due to a lack of reported dose-response and low compliance, leading to lower-than-expected exposure.&nbsp;
They highlighted upcoming milestones for CAHmelia-204 and suggested strategic dosing options, along with longer pivotal intentions for data from trials 204 and 205. However, they emphasized the need for a deeper understanding of the drug and its target patient population.&nbsp;
RBC downgraded its price target from $9 to $2 and shifted to a Sector Perform from Outperform.
JMP Securities&nbsp;noted that Tildacerfont did not demonstrate any significant effect on A4, likely due to poor compliance with medication and/or insufficient dosage, compounded by a challenging patient population, thus highlighting the importance of considering compliance issues in future assessments.
JMP Securities lowered its price target from $8 to $3 to maintain a Market Outperform rating.&nbsp;
Price Action: SPRB shares fell 84.38% to 81 cents on Thursday.
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37713530/tiktok-bidding-war-mnuchin-kotick-emerge-as-potential-buyers">TikTok Bidding War? Mnuchin, Kotick Emerge As Potential Buyers</a>
Image created using artificial intelligence with Midjourney.

Analyst Color

Movers

Trading Ideas

Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday.
The Dow traded down 0.35% to 38,905.20 while the NASDAQ fell 0.13% to 16,156.28. The S&amp;P 500 also fell, dropping, 0.25% to 5,152.46.
Check This Out: <a href="https://www.benzinga.com/news/24/03/37698150/tesla-to-165-here-are-10-top-analyst-forecasts-for-thursday"> Tesla To $165? Here Are 10 Top Analyst Forecasts For Thursday</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Energy shares jumped by 0.8% on Thursday.
In trading on Thursday, real estate shares fell by 2.4%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Dick&rsquo;s Sporting Goods Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dks#NYSE">DKS</a>) reported better-than-expected fourth-quarter results and issued strong guidance.
Dick&rsquo;s Sporting Goods reported fourth-quarter FY23 sales growth of 7.8% year-on-year to $3.876 billion, beating the analyst consensus estimate of $3.796 billion. Adjusted EPS of $3.85 beat the analyst consensus of $3.35.
Dick&rsquo;s Sporting Goods sees FY24 EPS of $12.85 &ndash; $13.25 versus the consensus of $12.90. The company expects FY24 net sales of $13 billion &ndash; $13.13 billion, against an estimate of $13.131 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Turtle Beach Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hear#NASDAQ">HEAR</a>) shares shot up 27% to $13.97 after the company announced the acquisition of PDP and its intention to launch a modified &quot;Dutch Auction&quot; Tender Offer. The company also reported fourth-quarter financial results.
Shares of VAALCO Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/egy#NYSE">EGY</a>) got a boost, surging 17% to $5.20 after the company reported better-than-expected fourth-quarter financial results.
Build-A-Bear Workshop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbw#NYSE">BBW</a>) shares were also up, gaining 18% to $29.45 after the company reported better-than-expected fourth-quarter EPS but missed on revenue. Additionally, the company guided FY24 revenue growth on a low-to-mid-single-digit percentage basis.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Spruce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprb#NASDAQ">SPRB</a>) shares dropped 80% to $1.0205 after the company reported FY23 financial results. Also, the company announced that the CAHmedlia-203 study of Tildacerfont in adult classic congenital adrenal hyperplasia with severe hyperandrogenemia did not meet its primary efficacy endpoint.
Shares of Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) were down 53% to $0.1507 following a Wall Street Journal report suggesting the company is preparing for a possible bankruptcy filing.
Better Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bttx#NASDAQ">BTTX</a>) was down, falling 81% to $0.0383. Better Therapeutics announced it will seek strategic alternatives and will be delisted from the Nasdaq.
Also Check This Out:<a href="https://www.benzinga.com/news/24/03/37699843/top-3-health-care-stocks-that-are-ticking-portfolio-bombs"> Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 2.2% to $81.44 while gold traded down 0.6% at $2,167.00.
Silver traded down 0.3% to $25.07 on Thursday, while copper fell 0.4% to $4.0420.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.18%, London&rsquo;s FTSE 100 fell 0.37% while Spain&rsquo;s IBEX 35 Index fell 0.66% The German DAX slipped 0.11% French CAC 40 rose 0.29% while Italy&rsquo;s FTSE MIB Index gained 0.29%.
Spain&rsquo;s annual inflation rate eased to 2.8% in February, the lowest in six months, compared to 3.4% in January.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Thursday, with Japan&rsquo;s Nikkei 225 gaining 0.29%, Hong Kong&rsquo;s Hang Seng Index falling 0.71%, China&rsquo;s Shanghai Composite Index falling 0.18% and India&rsquo;s S&amp;P BSE Sensex gaining 0.5%.
Manufacturing production in Hong Kong rose 4.1% year-over-year in the fourth quarter compared to a revised 4.3% gain in the prior period. Indian wholesale prices rose by 0.20% year-over-year in February versus a 0.27% increase in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The Producer Price Index for final demand in the U.S. increased by 0.6% month-over-month in February, higher than market expectations of a 0.3% rise.
U.S. retail sales increased 0.6% month-over-month in February compared to a revised 1.1% decline in January and down from market estimates of a 0.8% surge.
U.S. initial jobless claims declined by 1,000 to 209,000 in the week ended March 8, compared to market estimates of 218,000.
U.S. total business inventories came in flat month-over-month in January compared to a 0.3% increase in the previous month.
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37687466/how-to-earn-500-a-month-from-pfizer-stock-after-a-surprise-profit-turning-quarter"> How To Earn $500 A Month From Pfizer Stock After A Surprise Profit-Turning Quarter</a>

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

BTTX

HEAR

Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views

Shares of Limbach Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmb#NASDAQ">LMB</a>) fell sharply during Thursday&rsquo;s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Limbach said it sees FY24 revenue of $510 million to $530 million, versus market estimates of $541.1 million.
Limbach shares dipped 14.7% to $42.42 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Aptorum Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apm#NASDAQ">APM</a>) shares climbed 91% to $8.27.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) shares jumped 65.2% to $0.3715 after jumping 15% on Wednesday.</li>
<li>Cheer Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chr#NASDAQ">CHR</a>) surged 43.3% to $3.77 following full year 2023 financial results.</li>
<li>WiMi Hologram Cloud Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wimi#NASDAQ">WIMI</a>) shares gained 36.9% to $1.5060.</li>
<li>Turtle Beach Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hear#NASDAQ">HEAR</a>) gained 29.2% to $14.25 after the company announced the acquisition of PDP and its intention to launch a modified &quot;Dutch Auction&quot; Tender Offer. The company also reported fourth-quarter financial results.</li>
<li>VAALCO Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/egy#NYSE">EGY</a>) rose 22% to $5.45 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Build-A-Bear Workshop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbw#NYSE">BBW</a>) gained 15.7% to $29.20 after the company reported better-than-expected fourth-quarter EPS but missed on revenue. Additionally, the company guided FY24 revenue growth on a low-to-mid-single-digit percentage basis.</li>
<li>Unicycive Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uncy#NASDAQ">UNCY</a>) gained 15% to $1.5980. The company announced a $50 million private placement.</li>
<li>DICK&#39;S Sporting Goods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dks#NYSE">DKS</a>) rose 14.8% to $215.70 after the company reported strong fourth-quarter results and issued guidance above consensus estimates.</li>
<li>Lithium Americas Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lac#NYSE">LAC</a>) surged 14.6% to $6.57 after the company announced that it received a conditional commitment from the U.S. Department of Energy for a $2.26 billion loan under the Advanced Technology Vehicles Manufacturing Loan Program for financing the construction of the processing facilities at Thacker Pass in Nevada.</li>
<li>Auddia Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auud#NASDAQ">AUUD</a>) shares gained 11.5% to $3.07 after falling 6% on Wednesday.</li>
<li>Impinj, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pi#NASDAQ">PI</a>) gained 11.5% to $126.53 after the company announced a patent litigation settlement with NXP Semiconductors.</li>
<li>ShiftPixy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pixy#NASDAQ">PIXY</a>) gained 9.2% to $3.5501 after gaining over 3% on Wednesday.</li>
<li>CCSC Technology International Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cctg#NASDAQ">CCTG</a>) rose 8.7% to $3.6401 after gaining 14% on Wednesday.</li>
<li>Eventbrite, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eb#NYSE">EB</a>) surged 8.7% to $5.55. Eventbrite announced a $100 million share repurchase program.</li>
<li>Perfect Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/perf#NYSE">PERF</a>) gained 8.6% to $2.8550.</li>
<li>Robinhood Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) rose 6.3% to $18.24 after the company reported February trading metrics.</li>
<li>Spero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spro#NASDAQ">SPRO</a>) climbed 5.1% to $1.7450 following better-than-expected fourth-quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprb#NASDAQ">SPRB</a>) shares dipped 78.5% to $1.1150 after the company reported FY23 financial results. Also, the company announced that the CAHmedlia-203 study of Tildacerfont in adult classic congenital adrenal hyperplasia with severe hyperandrogenemia did not meet its primary efficacy endpoint.</li>
<li>Better Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bttx#NASDAQ">BTTX</a>) tumbled 78% to $0.0452. Better Therapeutics announced it will seek strategic alternatives and will be delisted from the Nasdaq.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) fell 49% to $0.1644 following a Wall Street Journal report suggesting the company is preparing for a possible bankruptcy filing.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) dipped 33.7% to $0.4182.</li>
<li>Immuneering Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrx#NASDAQ">IMRX</a>) fell 31.6% to $4.02 after the company announced topline results from Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in RAS-mutant solid tumors.</li>
<li>RCM Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcmt#NASDAQ">RCMT</a>) dipped 27.9% to $20.74 following weak quarterly sales.</li>
<li>Katapult Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kplt#NASDAQ">KPLT</a>) declined 27% to $13.44 following fourth-quarter results.</li>
<li>Hello Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/momo#NASDAQ">MOMO</a>) fell 24.1% to $5.82 after the company reported fourth-quarter financial results and issued first-quarter revenue guidance.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) dipped 23.8% to $4.9750. First Wave BioPharma announcec completion of business combination with ImmunogenX.</li>
<li>Pagaya Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgy#NASDAQ">PGY</a>) declined 22.5% to $12.02 after the company commenced an underwritten offering of 6.5 million shares.</li>
<li>RumbleON, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmbl#NASDAQ">RMBL</a>) fell 21.8% to $5.55 following weak quarterly sales.</li>
<li>Pangaea Logistics Solutions, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/panl#NASDAQ">PANL</a>) dipped 20% to $6.62 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Regulus Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgls#NASDAQ">RGLS</a>) tumbled 16.9% to $2.0188.</li>
<li>Petco Health and Wellness Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/woof#NASDAQ">WOOF</a>) fell 16.4% to $2.1050. Baird analyst Justin Kleber maintained Petco Health and Wellness with a Neutral and lowered the price target from $3 to $2.5.</li>
<li>G-III Apparel Group, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/giii#NASDAQ">GIII</a>) fell 16.3% to $25.37 following mixed fourth-quarter financial results. The company also issued lower-than-expected revenue and EPS guidance for FY25.</li>
<li>NextNav Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nn#NASDAQ">NN</a>) fell 15% to $4.7640 after posting a quarterly loss.</li>
<li>SentinelOne, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/s#NYSE">S</a>) dipped 14.9% to $23.78 after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Erayak Power Solution Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/raya#NASDAQ">RAYA</a>) fell 14.5% to $0.8025 after surging 31% on Wednesday.</li>
<li>Global Gas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hgas#NASDAQ">HGAS</a>) shares fell 13.3% to $2.15 after surging 16% on Wednesday.</li>
<li>Sunnova Energy International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nova#NYSE">NOVA</a>) declined 12.8% to $4.0540.</li>
<li>Highest Performances Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/puyi#NASDAQ">PUYI</a>) dipped 12.6% to $7.47.</li>
<li>Under Armour, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uaa#NYSE">UAA</a>) dipped 12.6% to $7.07 amid volatility following a CEO transition. Additionally, Williams Trading downgraded the stock from Buy to Hold and announced an $8 price target.</li>
<li>Vroom, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrm#NASDAQ">VRM</a>) shares tumbled 11.2% to $15.53 as the company reported a loss of $80.51 per share for the fourth quarter. The company&rsquo;s quarterly sales came in at $235.92 million which beat the analyst consensus estimate of $232 million.</li>
<li>Futu Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/futu#NASDAQ">FUTU</a>) shares fell 9.5% to $59.17 following fourth-quarter results.</li>
<li>Madrigal Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdgl#NASDAQ">MDGL</a>) fell 9.1% to $248.09.</li>
<li>Qilian International Holding Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qli#NASDAQ">QLI</a>) shares tumbled 8.8% to $0.5921 after surging 18% on Wednesday.</li>
<li>Affirm Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afrm#NASDAQ">AFRM</a>) fell 8.3% to $35.56.</li>
<li>UiPath Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/path#NYSE">PATH</a>) fell 6.8% to $22.72 after the company reported fourth-quarter financial results.</li>
<li>Anheuser-Busch InBev SA/NV (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bud#NYSE">BUD</a>) shares fell 4.7% to $61.51 after Altria announced its intent to sell a portion of its investment in the company.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37701714/ethereum-falls-below-4-000-following-ppi-data-bittensor-apecoin-among-top-losers"> Ethereum Falls Below $4,000 Following PPI Data; Bittensor, ApeCoin Among Top Losers </a>

AFRM

AUUD

CCTG

FUTU

FWBI

GIII

HGAS

HOOD

IMRX

KPLT

MDGL

MOMO

NOVA

PANL

PATH

PERF

PIXY

PRST

PUYI

RAYA

RCMT

RGLS

RMBL

SPRO

TCON

UNCY

WIMI

WOOF

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares rose 52.9% to $1.59 during Thursday's regular session. The company's market cap stands at $21.2 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock moved upwards by 43.65% to $6.22. The market value of their outstanding shares is at $32.2 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 17.27% to $1.29. The company's market cap stands at $19.0 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares moved upwards by 11.76% to $1.9. The company's market cap stands at $4.6 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares increased by 11.66% to $3.35. The market value of their outstanding shares is at $63.0 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock moved upwards by 11.65% to $1.82. The market value of their outstanding shares is at $135.9 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Better Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTTX#NASDAQ">BTTX</a>) stock fell 82.4% to $0.04 during Thursday's regular session. The market value of their outstanding shares is at $1.9 million. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock fell 79.57% to $1.06. The market value of their outstanding shares is at $43.1 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock fell 48.73% to $3.02. The market value of their outstanding shares is at $88.2 million. </li>
<li>Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) shares fell 26.43% to $19.0. The market value of their outstanding shares is at $219.1 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 22.57% to $0.36. The market value of their outstanding shares is at $3.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 22.48% to $0.49. The company's market cap stands at $22.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

CLSD

ISPC

MIRA

SNDA

TCBP

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday.
The Dow traded down 0.30% to 38,926.22 while the NASDAQ fell 0.44% to 16,107.04. The S&amp;P 500 also fell, dropping, 0.39% to 5,145.38.
Check This Out: <a href="https://www.benzinga.com/news/24/03/37698150/tesla-to-165-here-are-10-top-analyst-forecasts-for-thursday"> Tesla To $165? Here Are 10 Top Analyst Forecasts For Thursday</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Energy shares jumped by 0.4% on Thursday.
In trading on Thursday, real estate shares fell by 0.6%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Dollar General Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dg#NYSE">DG</a>) posted better-than-expected earnings for its fourth quarter on Thursday.
The company reported a four-quarter FY23 sales decline of 3.4% year-on-year to $9.858 billion, beating the analyst consensus estimate of $9.783 billion. EPS of $1.83 beat the consensus estimate of $1.75.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Turtle Beach Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hear#NASDAQ">HEAR</a>) shares shot up 27% to $13.99 after the company announced the acquisition of PDP and its intention to launch a modified &quot;Dutch Auction&quot; Tender Offer. The company also reported fourth-quarter financial results.
Shares of VAALCO Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/egy#NYSE">EGY</a>) got a boost, surging 24% to $5.51 after the company reported better-than-expected fourth-quarter financial results.
Build-A-Bear Workshop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbw#NYSE">BBW</a>) shares were also up, gaining 17% to $29.15 after the company reported better-than-expected fourth-quarter EPS but missed on revenue. Additionally, the company guided FY24 revenue growth on a low-to-mid-single-digit percentage basis.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Spruce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprb#NASDAQ">SPRB</a>) shares dropped 79% to $1.09 after the company reported FY23 financial results. Also, the company announced that the CAHmedlia-203 study of Tildacerfont in adult classic congenital adrenal hyperplasia with severe hyperandrogenemia did not meet its primary efficacy endpoint.
Shares of Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) were down 48% to $0.1668 following a Wall Street Journal report suggesting the company is preparing for a possible bankruptcy filing.
Better Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bttx#NASDAQ">BTTX</a>) was down, falling 80% to $0.0407. Better Therapeutics announced it will seek strategic alternatives and will be delisted from the Nasdaq.
Also Check This Out:<a href="https://www.benzinga.com/news/24/03/37699843/top-3-health-care-stocks-that-are-ticking-portfolio-bombs"> Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 1.9% to $81.20 while gold traded down 0.7% at $2,165.50.
Silver traded down 0.1% to $25.14 on Thursday, while copper fell 0.3% to $4.0495.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.07%, London&rsquo;s FTSE 100 fell 0.30% while Spain&rsquo;s IBEX 35 Index fell 0.47% The German DAX slipped 0.02% French CAC 40 rose 0.51% while Italy&rsquo;s FTSE MIB Index gained 0.03%.
Spain&rsquo;s annual inflation rate eased to 2.8% in February, the lowest in six months, compared to 3.4% in January.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Thursday, with Japan&rsquo;s Nikkei 225 gaining 0.29%, Hong Kong&rsquo;s Hang Seng Index falling 0.71%, China&rsquo;s Shanghai Composite Index falling 0.18% and India&rsquo;s S&amp;P BSE Sensex gaining 0.5%.
Manufacturing production in Hong Kong rose 4.1% year-over-year in the fourth quarter compared to a revised 4.3% gain in the prior period. Indian wholesale prices rose by 0.20% year-over-year in February versus a 0.27% increase in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The Producer Price Index for final demand in the U.S. increased by 0.6% month-over-month in February, higher than market expectations of a 0.3% rise.
U.S. retail sales increased 0.6% month-over-month in February compared to a revised 1.1% decline in January and down from market estimates of a 0.8% surge.
U.S. initial jobless claims declined by 1,000 to 209,000 in the week ended March 8, compared to market estimates of 218,000.
U.S. total business inventories came in flat month-over-month in January compared to a 0.3% increase in the previous month.
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37687466/how-to-earn-500-a-month-from-pfizer-stock-after-a-surprise-profit-turning-quarter"> How To Earn $500 A Month From Pfizer Stock After A Surprise Profit-Turning Quarter</a>

Crude Oil Moves Higher; Dollar General Posts Upbeat Earnings

RBC Capital analyst Gregory Renza downgrades Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) from Outperform to Sector Perform and lowers the price target from $9 to $2.

Downgrades

RBC Capital Downgrades Spruce Biosciences to Sector Perform, Lowers Price Target to $2

U.S. stocks traded higher this morning, following the release of PPI data.
Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&amp;P 500 also rose, gaining, 0.14% to 5,172.33.
Check This Out: <a href="https://www.benzinga.com/news/24/03/37698150/tesla-to-165-here-are-10-top-analyst-forecasts-for-thursday"> Tesla To $165? Here Are 10 Top Analyst Forecasts For Thursday</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Energy shares jumped by 0.4% on Thursday.
In trading on Thursday, real estate shares fell by 0.6%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The Producer Price Index for final demand in the U.S. increased by 0.6% month-over-month in February, higher than market expectations of a 0.3% rise.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) shares shot up 77% to $0.3987 after jumping 15% on Wednesday.
Shares of Aptorum Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apm#NASDAQ">APM</a>) got a boost, surging 69% to $7.30.
WiMi Hologram Cloud Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wimi#NASDAQ">WIMI</a>) shares were also up, gaining 35% to $1.49.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Spruce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprb#NASDAQ">SPRB</a>) shares dropped 78% to $1.1496 after the company reported FY23 financial results. Also, the company announced that the CAHmedlia-203 study of Tildacerfont in adult classic congenital adrenal hyperplasia with severe hyperandrogenemia did not meet its primary efficacy endpoint.
Shares of Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) were down 50% to $0.1620 following a Wall Street Journal report suggesting the company is preparing for a possible bankruptcy filing.
Immuneering Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrx#NASDAQ">IMRX</a>) was down, falling 27% to $4.2825 after the company announced topline results from Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in RAS-mutant solid tumors.
Also Check This Out:<a href="https://www.benzinga.com/news/24/03/37699843/top-3-health-care-stocks-that-are-ticking-portfolio-bombs"> Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 1.2% to $80.66 while gold traded down 0.5% at $2,169.10.
Silver traded up 0.5% to $25.285 on Thursday, while copper fell 0.3% to $4.0485.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 rose 0.1%, London&rsquo;s FTSE 100 fell 0.1% while Spain&rsquo;s IBEX 35 Index fell 0.3% The German DAX gained 0.1% French CAC 40 rose 0.6% while Italy&rsquo;s FTSE MIB Index gained 0.2%.
Spain&rsquo;s annual inflation rate eased to 2.8% in February, the lowest in six months, compared to 3.4% in January.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Thursday, with Japan&rsquo;s Nikkei 225 gaining 0.29%, Hong Kong&rsquo;s Hang Seng Index falling 0.71%, China&rsquo;s Shanghai Composite Index falling 0.18% and India&rsquo;s S&amp;P BSE Sensex gaining 0.5%.
Manufacturing production in Hong Kong rose 4.1% year-over-year in the fourth quarter compared to a revised 4.3% gain in the prior period. Indian wholesale prices rose by 0.20% year-over-year in February versus a 0.27% increase in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The Producer Price Index for final demand in the U.S. increased by 0.6% month-over-month in February, higher than market expectations of a 0.3% rise.
U.S. retail sales increased 0.6% month-over-month in February compared to a revised 1.1% decline in January and down from market estimates of a 0.8% surge.
U.S. initial jobless claims declined by 1,000 to 209,000 in the week ended March 8, compared to market estimates of 218,000.
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37687466/how-to-earn-500-a-month-from-pfizer-stock-after-a-surprise-profit-turning-quarter"> How To Earn $500 A Month From Pfizer Stock After A Surprise Profit-Turning Quarter</a>

US Stocks Higher; Producer Prices Rise 0.6% In February

HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgrades Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) from Buy to Neutral.

HC Wainwright & Co. Downgrades Spruce Biosciences to Neutral

Wednesday,&nbsp;Spruce Biosciences Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) released topline results from its CAHmelia-203 Phase 2b study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/b37675328/spruce-biosciences-announces-topline-results-from-cahmelia-203-in-adult-classic-cah-and-cahptain-2" rel="noreferrer noopener">pediatric classic CAH</a>.
CAH refers to a group of genetic disorders that involve the adrenal glands, a pair of small organs located above the kidneys.
The CAHmelia-203 study did not achieve the primary efficacy endpoint of the assessment of dose response for the change in A4 from baseline to week 12.
<ul>
<li>200mg QD of tildacerfont demonstrated a placebo-adjusted reduction from baseline in A4 of -2.6% at week 12 with a non-significant p-value.</li>
<li>&nbsp;Compliance with study medication and GC was low, with approximately 50% of patients reporting 80% or greater compliance, resulting in lower-than-expected tildacerfont exposure.</li>
<li>&nbsp;Tildacerfont was generally safe and well tolerated at all doses with no treatment-related serious adverse events (SAEs). Most adverse events were reported as mild to moderate.s</li>
</ul>
CAHptain-205 study enrolled 30 children.
<ul>
<li>Tildacerfont was generally safe and well tolerated at all dose ranges with no treatment-related SAEs reported.</li>
<li>&nbsp;Preliminary pharmacokinetic analysis suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.</li>
<li>&nbsp;73% of all patients (22 of 30) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks of treatment with tildacerfont.</li>
<li>&nbsp;70% of patients with elevated baseline A4 values (16 of 23 patients) demonstrated an A4 reduction at week 4.</li>
<li>&nbsp;The company says data from the CAHptain-205 study supports further dose-ranging across additional cohorts.</li>
</ul>
The company is also conducting CAHmelia-204 Phase 2b study assessing glucocorticoid (GC) reduction, a potentially registrational endpoint in adult CAH patients on supraphysiologic GC doses with normal or near normal levels of A4. Topline results are expected in Q3 2024.
In January, Spruce Biosciences said it completed enrollment in its CAHmelia-204 trial, with 100 patients exceeding the target&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/b36714215/spruce-biosciences-completes-enrollment-in-cahmelia-204-study-for-adult-classic-congenital-adrenal" rel="noreferrer noopener">enrollment of 90</a>.
The company says resource prioritization and cost reductions, including termination of the CAHmelia-203 trial and a reduction in force of approximately 21%, will extend the cash runway through the end of 2025, including beyond anticipated topline results from CAHmelia-204 and additional dose-ranging&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/b37675676/spruce-biosciences-reports-full-year-2023-financial-results-and-provides-corporate-updates" rel="noreferrer noopener">data from CAHptain-205</a>.
Price Action:&nbsp;SPRB shares are down 77.80% at $1.15 during the premarket session on the last check Thursday.

Guidance

Why Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?

<h3>Gainers</h3>
<ul>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock moved upwards by 23.65% to $11.92. The company's market cap stands at $211.8 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) stock moved upwards by 20.99% to $0.34. The market value of their outstanding shares is at $62.5 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) shares rose 14.38% to $1.59. The market value of their outstanding shares is at $55.2 million. </li>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) shares rose 13.57% to $8.2. The company's market cap stands at $251.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) stock moved upwards by 13.34% to $6.54. The company's market cap stands at $511.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 78.0% to $1.14 during Thursday's pre-market session. The company's market cap stands at $46.4 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock decreased by 15.65% to $0.1. The company's market cap stands at $4.0 million. </li>
<li>Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) stock decreased by 12.04% to $2.12. The market value of their outstanding shares is at $464.3 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) stock declined by 9.15% to $5.76. The market value of their outstanding shares is at $3.9 billion. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares decreased by 8.97% to $0.59. The company's market cap stands at $21.1 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock fell 8.39% to $0.45. The company's market cap stands at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANNX

BGXX

BPTS

GRFS

Kintara Therapeutics, Inc. - Common Stock

KTRA

NUVB

NVCT

TELO

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tyra Bioscience (TYRA – Research Report), Spruce B...

Analysts Conflicted on These Healthcare Names: Tyra Bioscience (TYRA), Spruce Biosciences (SPRB) and UnitedHealth (UNH)

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Spruce Biosciences (SPRB – Research Report) today. The company's shares closed ye...

H.C. Wainwright Remains a Hold on Spruce Biosciences (SPRB)

Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating on Spruce Biosciences (SPRB – Research Report) and keeping the price target a...

Optimistic Outlook for Spruce Biosciences: Tildacerfont's Market Potential Amidst Upcoming Trial Data

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Spruce Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sprb-stock-quote/">SPRB</a>) just reported results for the second quarter of 2024.<ul><li>Spruce Biosciences reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -30 cents.</li><li>The company reported revenue of $1.61 million.</li><li>This was 7.69% better than the analyst estimate for revenue of $1.50 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sprb-stock-earnings-spruce-biosciences-for-q2-of-2024/">SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024

Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Spruce Biosciences (SPRB – Research Report). The associated price t...

Buy Rating Affirmed for Spruce Biosciences Amid Anticipated Positive Clinical Trial Outcomes and Strong Financial Position

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Meiragtx Holdings (MGTX – Research Report), Spruce Biosciences (S...

Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)

Spruce Biosciences GAAP EPS of -$0.22 beats by $0.01, revenue of $1.61M beats by $0.69M

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kronos Bio (KRON – Research Report), Spruce Biosciences (SPRB – R...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and scPharmaceuticals (SCPH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pyxis Oncology (PYXS – Research Report), Spruce Biosciences (SPRB...

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acrivon Therapeutics, Inc. (ACRV – Research Report) ...

Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Spruce Biosciences (SPRB)

ACRV

GOSS

KRON

MGTX

NVST

PYXS

SCPH

TYRA

Press Releases

Spruce Biosciences to Participate in May Investor Conferences

Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference

Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Spruce Biosciences Recognized as a Bay Area Best Place to Work

Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

Comments

Spruce Biosciences

Notizie

Ultime notizie per Spruce Biosciences (NASDAQ:SPRB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO